Global Leading Market Research Publisher QYResearch announces the release of its latest report “HPV Vaccine for Men (Male HPV Vaccine) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”.
For public health officials, vaccine procurement directors, and infectious disease strategists, the paradigm of Human Papillomavirus (HPV) vaccination has long been associated with cervical cancer prevention in women. This focus, while justified, has historically overshadowed the significant and preventable burden of HPV-related disease in males. Men are not only vectors of transmission but are directly affected by HPV-associated malignancies, including penile cancer, anal cancer, and oropharyngeal (throat) cancer, as well as benign but highly morbid conditions such as genital warts.
Male HPV vaccination—the administration of quadrivalent or nonavalent HPV vaccines to boys and young men—offers direct personal protection against these diseases and contributes to herd immunity, accelerating the population-level impact of immunization programs. This report provides a clinically grounded, source-segmented assessment of this emerging preventive healthcare market, valued at US$22 million in 2024 and projected to reach US$35.3 million by 2031, expanding at a CAGR of 7.1% , driven by expanding gender-neutral vaccination policies, increasing awareness of HPV-related male cancers, and the entry of domestic vaccine manufacturers into markets previously dependent on a single global supplier.
[Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)]
https://www.qyresearch.com/reports/4661996/hpv-vaccine-for-men-male-hpv-vaccine
I. Market Scale & Trajectory: From Female-Focused to Gender-Neutral
According to QYResearch’s newly published database, the global HPV Vaccine for Men (Male HPV Vaccine) market was valued at US$22 million in 2024 and is projected to reach US$35.3 million by 2031, reflecting a CAGR of 7.1% .
Critical insight for decision-makers: This 7.1% CAGR is not a simple extrapolation of female vaccination trends. It reflects three structural, policy-and-epidemiological drivers: (1) the progressive adoption of gender-neutral HPV vaccination programs by an increasing number of national immunization technical advisory groups (NITAGs) ; (2) rising public and professional awareness of the link between high-risk HPV types (16, 18, and others) and the rising incidence of oropharyngeal cancer in men; and (3) the gradual alleviation of global vaccine supply constraints, enabling expanded access to male cohorts.
Market structure by vaccine source:
- Imported Vaccines: ~75–80% of revenue. Primarily Merck’s Gardasil (quadrivalent) and Gardasil 9 (nonavalent). Established efficacy and safety profile; global supply chain; premium pricing. Volume anchor in developed markets and private-payer segments.
- Domestic Vaccines: ~20–25% of revenue and fastest-growing segment. Chinese-manufactured HPV vaccines (Wantai Biotech, Kangle Guardian, Bovaxbio) are expanding domestic access and, increasingly, pursuing WHO prequalification for global distribution. Cost-advantaged; critical for public-sector programs in price-sensitive markets.
Market structure by disease prevention application:
- Genital Warts: ~50–55% of revenue. Primary endpoint for early adoption; visible, high-burden outcome. Dominant in adolescent and young adult male vaccination.
- Penile Cancer and Precancerous Lesions: ~15–20% of revenue. Rare but devastating malignancy; direct causal link to HPV 16/18. Key driver for adult male catch-up programs.
- Perianal Cancer and Precancerous Lesions: ~15–20% of revenue. Rising incidence; particularly relevant in men who have sex with men (MSM) and immunocompromised populations.
- Perineal Cancer and Precancerous Lesions: ~10–15% of revenue. Overlapping anatomical region with genital and perianal cancers; included in comprehensive male HPV disease burden assessments.
- Others (Oropharyngeal Cancer, Recurrent Respiratory Papillomatosis) : ~5% of revenue and emerging.
II. Disease Burden & Clinical Rationale: Beyond Cervical Cancer
To appreciate the market’s clinical and public health rationale, one must first understand the underrecognized burden of HPV-associated disease in males.
HPV Prevalence in Males:
- HPV infection is common in sexually active males; lifetime risk of acquiring at least one genital HPV type is >80% .
- Prevalence peaks in young adults (18–30 years) and remains substantial throughout life.
HPV-Associated Malignancies in Males:
- Oropharyngeal Cancer: Incidence is rising rapidly in developed countries, now exceeding cervical cancer incidence in the US. >70% are attributable to HPV 16.
- Anal Cancer: Incidence is increasing, particularly in MSM and HIV-positive men. >80% attributable to HPV 16/18.
- Penile Cancer: Rarer but highly morbid; 40–50% attributable to HPV 16/18.
Benign Disease:
- Genital Warts: Caused by HPV 6 and 11. High incidence; significant psychosocial morbidity; substantial healthcare utilization for treatment.
Herd Immunity Effect:
- Mathematical modeling and empirical data demonstrate that vaccinating males accelerates HPV circulation reduction, providing indirect protection to unvaccinated females and MSM.
The strategic takeaway: Male HPV vaccination is not “vaccinating boys to protect girls.” It is direct personal protection against a range of preventable cancers and diseases, with the added benefit of population-level transmission reduction. This reframing is critical for public acceptance and policy adoption.
III. Industry Characteristics: The Five Pillars of an Emerging, Supply-Constrained Market
For public health executives, vaccine manufacturers, and investors evaluating this space, five structural characteristics define the current and future competitive landscape.
Pillar 1: The Single-Supplier Legacy (Merck)
For over a decade, Merck’s Gardasil (quadrivalent) and Gardasil 9 (nonavalent) were the only HPV vaccines available globally. This created a supply-constrained, price-inelastic market, with priority allocation to female national immunization programs. Male vaccination was largely confined to private-payer markets and opportunistic catch-up.
Pillar 2: The Chinese Supply Inflection
The entry of Chinese manufacturers (Wantai Biotech (Cecolin), Kangle Guardian, Bovaxbio) with WHO-prequalified or prequalification-track HPV vaccines is fundamentally reshaping the supply landscape. Increased production capacity is alleviating global shortages, enabling price competition, and expanding access to male cohorts in public-sector programs, particularly in low- and middle-income countries.
Pillar 3: Gender-Neutral Policy Adoption
As of 2024, over 50 countries have implemented gender-neutral HPV vaccination programs. The UK, Australia, Canada, and several European nations were early adopters. The US CDC’s Advisory Committee on Immunization Practices (ACIP) recommends routine HPV vaccination for males aged 11–12 and catch-up through age 21 (and through age 26 for MSM and immunocompromised men). Policy expansion is the single most important demand-side growth driver.
Pillar 4: The Oropharyngeal Cancer Awareness Gap
Public awareness of the link between HPV and throat cancer in men remains significantly lower than awareness of the link between HPV and cervical cancer in women. This awareness gap suppresses demand for adult male catch-up vaccination. Educational campaigns by public health authorities and patient advocacy groups are essential for market expansion beyond adolescent cohorts.
Pillar 5: The MSM and Immunocompromised Priority Populations
Men who have sex with men (MSM) and men living with HIV are at significantly elevated risk for HPV acquisition and HPV-associated cancers. Targeted vaccination programs for these priority populations are a high-impact, cost-effective intervention and a growing market segment.
IV. Competitive Landscape: Global Leader and Domestic Challengers
The male HPV vaccine competitive arena is transitioning from a single-supplier market to a multi-supplier, price-stratified market:
- Global Leader: Merck & Co. (Gardasil, Gardasil 9) . Established efficacy and safety database; strong intellectual property position; premium pricing; global distribution network. Gross margins: 80–90% .
- Chinese Domestic Challengers: Wantai Biotech (Cecolin), Kangle Guardian, Bovaxbio. Cost-advantaged; expanding domestic and international presence; pursuing WHO prequalification; critical for public-sector access. Gross margins: 60–75% .
Differentiation vectors: Valency (9-valent vs. 4-valent vs. 2-valent), efficacy duration, price, and WHO prequalification status.
V. Strategic Imperatives: 2026–2031
Imperative 1: Policy Advocacy for Gender-Neutral Inclusion
Expanding male vaccination requires sustained advocacy with NITAGs and health ministries. Suppliers must engage in health economics research, public awareness campaigns, and policy dialogue to support guideline expansion.
Imperative 2: Adult Male Catch-Up Market Development
The adolescent male cohort is the volume anchor, but the adult male catch-up market (ages 19–45) represents significant incremental value. Suppliers must develop communication strategies tailored to this demographic, emphasizing oropharyngeal cancer prevention.
Imperative 3: Supply Chain Expansion to LMICs
Low- and middle-income countries (LMICs) have the greatest unmet need for HPV vaccination in both sexes. Suppliers with WHO-prequalified vaccines and sustainable tiered pricing models will capture significant long-term volume.
Imperative 4: MSM and HIV Population Engagement
Public health programs targeting MSM and men living with HIV are a high-impact, high-return investment. Suppliers must partner with community-based organizations, HIV clinics, and LGBTQ+ health centers to reach these priority populations.
VI. Exclusive Insight: The “Catch-Up” Cohort Opportunity
The adolescent male cohort (age 11–12) is the primary target for routine vaccination, but the size of the adult male “catch-up” cohort (age 19–45) is substantially larger and largely unvaccinated. Even modest penetration of this cohort would double or triple the addressable market. This is the single greatest medium-term market expansion opportunity.
VII. Conclusion
The HPV Vaccine for Men market, with US$35.3 million in projected 2031 revenue and a 7.1% CAGR , is an emerging, policy-driven preventive healthcare category transitioning from a female-focused legacy to a gender-neutral standard-of-care.
For public health officials and vaccine procurement directors, male HPV vaccination offers a cost-effective, evidence-based intervention to reduce the burden of genital warts, anal cancer, penile cancer, and oropharyngeal cancer.
For vaccine manufacturers and investors, the thesis is 7.1% CAGR, 60–90% gross margins for differentiated products, and significant headroom for market expansion through policy adoption and adult catch-up campaigns. Success will be determined by WHO prequalification, price competitiveness, and effective communication of the direct personal benefit to males.
The complete market sizing, policy adoption timelines, and competitive landscape analysis are available in the full QYResearch report.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
